Overview

An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

This is an open label, single arm study which enrolled 5 subjects with SCD who previously participated in the GBT440-001 study (NCT02285088).

Phase:

Phase 2

Details

Lead Sponsor:

Global Blood Therapeutics